CLP has assisted Bionor Pharma in its NOK 1 billion acquisition of Solon Eiendom AS, and will assist Bionor Pharma in a contemplated private placement and subsequent offering with a total value of NOK 400 million to be completed within mid-January 2017. The acquisition represents a shift in strategy for Bionor Pharma, as it will now focus on residential property development.

CLP’s team has been led by Andreas Kildal and Håvard R. Skogvoll, and has also consisted of Edvard Cock, Jørgen G. Gran, Mathias Borch, Kelly Louise Amory and Joakim Gjerde.

For further information about the acquisition and contemplated equity issues, please see here.